# Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis

> **NCT04120519** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis

## Interventions

- **DRUG:** thalidomide combined with dexamethasone and cyclophosphamide

## Key facts

- **NCT ID:** NCT04120519
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120519, "Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04120519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*